Abstract 368P
Background
Oral Submucous Fibrosis (OSMF) is a chronic debilitating disease more frequently found in the South East Asian population. This disease poses a public health priority, as it is grouped under oral potentially malignant disorders, with malignant transformation rates of around 7 to 13%. Hence, early identification of high-risk OSMF patients is of the utmost importance to prevent malignant transformation. mRNA expression profiling is a promising method for identifying differentially expressed genes for disease prognosis in OSMF. The genetic profiling was performed using Tumor Signaling (TS) 360 Panel (Nanostring platform) to profile 780 humans across 40+ annotated pathways.
Methods
The RNA was initially isolated from patient tissue samples in different clinical stages of OSMF (n=8), OSMF transformed into oral squamous cell carcinoma (OSCC) (n=5) and healthy controls (HC) (n=5). The analysis of gene expression was conducted on the nCounter® TS 360™ Panel and NanoString platform. The raw transcriptome data were subjected to housekeeping-gene normalization using the geNorm algorithm in nCounter Advanced Analysis ver. 2.0.115. Normalized data were log2-transformed for analysis. A quality check of raw data was conducted using nSolver Analysis Software ver. 4.0 and NanoStringQCpro ver. 1.14.0.
Results
Among the 780 genes, AR, RPTOR and PRDX6 showed the highest differential expression between OSMF and OSCC (2.48, 1.1 and 0.76 fold change, respectively; p < 0.05). While, MLANA, WEE1 and MYB showed the highest differential expression between HC and OSCC (5.16, 2.61 and 2.11 fold change, respectively; p < 0.05). The upregulated genes were further validated using real time PCR which showed significant upregulation in OSMF and OSCC.
Conclusions
The present study is the first of its kind in India to the best of our knowledge, assessing the gene expression using the Nanostring platform in different clinical stages of OSMF. with validation in a large series of cases. The currenty study has evolved a panel of biomarkers, namely PRDX6, MLANA and AR to be potentially useful in identifying high-risk OSMF patients with an increased risk of OSCC development.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
C.V. Divyambika; R. Vijayalakshmi.
Funding
Indian Council of Medical Research (ICMR): 5/4/2-4/Oral Health/2021/NCD-II.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
193P - Impact of coronavirus disease 2019 on patients with unresectable hepatocellular carcinoma treated with atezolizumab/bevacizumab
Presenter: Hongjae Chon
Session: Poster Display
Resources:
Abstract
194P - Real-world outcomes of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus chemotherapy as first-line treatment in advanced gastric (G) or gastroesophageal junction (GEJ) cancer with PD-L1 CPS≤5
Presenter: Qi Xu
Session: Poster Display
Resources:
Abstract
195P - Ferroptosis signatures in pancreatic ductal adenocarcinomas and their role in patient survival: A translational unsupervised clustering analysis
Presenter: Quoc-Huy Trinh
Session: Poster Display
Resources:
Abstract
196P - Clinical significance of circulating CD8+ and CD4+ T cell proliferation in advanced gastric cancer receiving first-line chemotherapy
Presenter: In-Ho Kim
Session: Poster Display
Resources:
Abstract
197P - Treatment patterns and clinical outcomes of patients with unresectable advanced or metastatic (UAM) gastric/gastroesophageal junction adenocarcinoma (GA/GEJA) in China: A multicenter real-world study
Presenter: Yanqiao Zhang
Session: Poster Display
Resources:
Abstract
198P - Effectiveness of lenvatinib in patients with unresectable hepatocellular carcinoma: A multicenter observational study in Japan
Presenter: Namiki Izumi
Session: Poster Display
Resources:
Abstract
199P - Efficacy of endostar in combination with concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of esophagus: A randomized, open-label, phase II trial
Presenter: Yuexiao Qi
Session: Poster Display
Resources:
Abstract
200P - Prognosis of patients with hepatocellular carcinoma treated with transarterial chemoembolization: Development and validation of the ALFP score
Presenter: Baocuo Gong
Session: Poster Display
Resources:
Abstract
201P - A phase II study of serplulimab (a programmed death-1 inhibitor) with or without HLX04 (a bevacizumab biosimilar) for the treatment of advanced hepatocellular carcinoma
Presenter: Zhenggang Ren
Session: Poster Display
Resources:
Abstract
202P - Comparison of liver injury after transcatheter arterial chemoembolization and hepatic arterial infusion chemotherapy for intermediate and advanced hepatocellular carcinoma
Presenter: Yongru Chen
Session: Poster Display
Resources:
Abstract